- $289.46bn
- $331.15bn
- $56.33bn
Novartis experimental drug for ALS fails, Bloomberg News reports
Brief: Novartis Experimental Drug For ALS Fails In Another Pipeline Hit- Bloomberg News
Legend Biotech taps Novartis veteran Zhang as CEO (updated)
L'Oreal steals French stock market crown from LVMH (updated)
Legend Biotech taps Novartis veteran Zhang as CEO
US stocks weekly: Yields bite
Mizuho International - Sandoz Stabilisation Notice
Corrected: UPDATE 3-Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11)
US FDA approves Scholar Rock's muscle weakness drug
US stocks weekly: Yields bite
For Novartis, M&A is both a disease and cure
Focus: Novartis investors turn spotlight on M&A after trial setbacks
Major Novartis shareholder calls for board shake-up after drug trial setbacks
Major Novartis shareholder calls for board shake-up after drug trial setbacks
Europe Research Roundup: AstraZeneca, GSK, Kingspan Group
Roche's sustained growth visibility, Novartis' execution risks - RBC initiates coverage
Swiss stocks - Factors to watch on September 9
Asia Morning Call-Global Markets (updated)
Live Markets: Back to the post-summer grind: Stocks end red